Acarbose: An Old Diabetes Drug With New Longevity Questions

In this episode, Dr. David examines acarbose, a long-standing diabetes medication that has recently gained attention for its potential role in longevity and cardiovascular prevention. He breaks down how acarbose works as an alpha-glucosidase inhibitor, why it has historically been underused in clinical practice, and what renewed interest has emerged from animal longevity research. Dr. Day reviews data from mouse studies suggesting lifespan extension, then analyzes human clinical trials evaluating acarbose’s impact on diabetes prevention, cardiovascular events, and blood pressure. He compares findings from the STOP-NIDDM trial and the later ACE trial, addressing why their results differ and what that means for real-world application. The episode closes with a balanced discussion of potential benefits, risks, costs, and which patient populations may reasonably consider acarbose as part of a longevity-focused strategy.Key Points From This Episode:(00:00:00) Introduction to longevity trends and interest in medical interventions beyond lifestyle optimization(00:02:05) Why patients seek clarity on supplements, peptides, hormones, and longevity medications(00:03:36) Overview of acarbose as an older, underused diabetes medication(00:05:10) Explanation of alpha-glucosidase inhibitors and carbohydrate digestion(00:07:45) How acarbose blunts post-meal glucose and insulin spikes(00:09:32) Reasons acarbose fell out of favor, including modest glucose lowering and GI side effects(00:11:28) Potential gut microbiome benefits related to carbohydrate fermentation(00:13:05) Introduction to the NIH Interventions Testing Program and mouse longevity studies(00:14:42) Lifespan extension findings in male mice and proposed mechanisms(00:17:18) Overview of the STOP-NIDDM trial and diabetes prevention outcomes(00:19:06) Cardiovascular findings from STOP-NIDDM, including reduced heart attacks and hypertension(00:21:55) Review of the ACE trial and lack of cardiovascular benefit in high-risk patients(00:24:48) Comparison of trial populations, dosing differences, and baseline risk factors(00:28:10) Interpretation of conflicting trial results and implications for future research(00:31:05) Framework for evaluating longevity medications: benefit, mechanism, risk, and cost(00:33:18) Practical considerations, side effects, and patient profiles that may benefit(00:35:12) Final thoughts on acarbose as a low-cost, low-risk option for select individualsLinks:BetterLife: https://www.joinbetterlife.com/about-usDr. David Janarious on LinkedIn: https://www.linkedin.com/in/david-janarious-8b6073280Production and editing by The Podcast Consultant: https://thepodcastconsultant.com